The FDA approval of Spravato is a breakthrough for treatment-resistant depression, offering patients rapid relief.
The U.S. Food and Drug Administration (FDA) has officially approved Spravato (esketamine) nasal spray as a standalone treatment for adults with treatment-resistant depression (TRD).
This groundbreaking decision marks a new chapter in the fight against major depressive disorder (MDD), offering hope to those who have struggled to find relief through traditional treatments.
Read on to learn more about the FDA approval of Spravato and what it means for our patients:
What the FDA approval of Spravato means
Spravato’s approval as a standalone therapy is significant for the approximately 21 million adults in the United States living with MDD. Among them, one-third are classified as having treatment-resistant depression, meaning they have not responded to at least two different oral antidepressants. For these individuals, the FDA approval of Spravato opens a door to faster, more effective symptom relief.
Unlike conventional antidepressants that target serotonin or norepinephrine, Spravato works on the brain’s glutamate system, a novel approach that helps restore brain connectivity and improve mood more rapidly. Clinical trials showed that patients experienced relief from depressive symptoms within just 24 hours, with sustained improvement through 28 days.
Why Spravato is a game-changer
Traditional treatments for TRD often require weeks or months to show results, leaving many patients feeling stuck and hopeless. With Spravato, the treatment process is different:
- Rapid Relief: Clinical trials demonstrated significant symptom improvement within 24 hours, giving patients a sense of hope much sooner.
- Efficacy Backed by Research: By week four of the trial, over 22% of patients treated with Spravato achieved remission, compared to only 7.6% on a placebo.
- New Accessibility: With its approval as a monotherapy, Spravato offers a standalone option for patients who prefer not to combine it with oral antidepressants.
How Spravato is administered
Spravato is delivered as a nasal spray in a clinical setting under the supervision of a healthcare provider. This ensures that patients receive the proper dosage and monitoring for any potential side effects, such as dizziness or increased blood pressure. Each session lasts approximately two hours, during which patients are closely observed for safety and comfort.
What this means for patients
The FDA approval of Spravato is a game-changer for individuals who have felt trapped by the limitations of traditional antidepressants. For patients seeking relief from the burden of depression, this treatment offers a faster path to recovery with fewer barriers to access.
As Dr. Bill Martin of Johnson & Johnson explains, “With Spravato now approved as a monotherapy, patients have access to a treatment that offers meaningful symptom improvement as early as 24 hours, continuing through 28 days, without the need for daily oral antidepressants.”
Why choose Sonder for Spravato (esketamine) treatment
At Sonder, we’re proud to offer Spravato as part of our commitment to providing cutting-edge, compassionate care. Our experienced team ensures every patient receives personalized treatment in a safe and supportive environment. From the initial consultation to ongoing care, we’ll work closely with you to maximize the benefits of Spravato.
Take the next step toward relief
If you’re living with treatment-resistant depression and traditional methods haven’t worked for you, Spravato may be the breakthrough you’ve been waiting for. Contact us today to learn more about this innovative treatment and find out if it’s right for you.
Ready to experience Spravato (esketamine) at Sonder for yourself?